Chris Cooley
Stock Analyst at Stephens & Co.
(3.09)
# 1,111
Out of 5,182 analysts
55
Total ratings
71.05%
Success rate
44.18%
Average return
Main Sectors:
Stocks Rated by Chris Cooley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCEL Vericel | Maintains: Overweight | $39 → $42 | $36.98 | +13.57% | 2 | May 11, 2023 | |
| ALGN Align Technology | Maintains: Overweight | $500 → $375 | $184.70 | +103.03% | 7 | Jul 28, 2022 | |
| COO The Cooper Companies | Maintains: Overweight | $125 → $115 | $64.34 | +78.74% | 9 | Jun 3, 2022 | |
| ALC Alcon | Upgrades: Overweight | $86 → $92 | $76.01 | +21.04% | 4 | May 12, 2022 | |
| PLSE Pulse Biosciences | Maintains: Overweight | $14 → $12 | $22.65 | -47.02% | 2 | Apr 1, 2022 | |
| ANIK Anika Therapeutics | Downgrades: Equal-Weight | n/a | $15.81 | - | 2 | Mar 9, 2022 | |
| ESTA Establishment Labs Holdings | Maintains: Overweight | $88 → $90 | $65.47 | +37.47% | 3 | Nov 10, 2021 | |
| STE STERIS | Maintains: Overweight | $255 → $270 | $222.19 | +21.52% | 5 | Nov 4, 2021 | |
| GKOS Glaukos | Upgrades: Overweight | $60 → $68 | $122.07 | -44.29% | 5 | Nov 3, 2021 | |
| AVNS Avanos Medical | Downgrades: Equal-Weight | $60 → $45 | $24.62 | +82.78% | 2 | Aug 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $425 → $275 | $135.07 | +103.60% | 5 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $56 → $37 | $26.68 | +38.68% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $60 | $61.41 | -2.30% | 3 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $35 | $59.95 | -41.62% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $60 → $81 | $188.31 | -56.99% | 2 | Feb 22, 2018 |
Vericel
May 11, 2023
Maintains: Overweight
Price Target: $39 → $42
Current: $36.98
Upside: +13.57%
Align Technology
Jul 28, 2022
Maintains: Overweight
Price Target: $500 → $375
Current: $184.70
Upside: +103.03%
The Cooper Companies
Jun 3, 2022
Maintains: Overweight
Price Target: $125 → $115
Current: $64.34
Upside: +78.74%
Alcon
May 12, 2022
Upgrades: Overweight
Price Target: $86 → $92
Current: $76.01
Upside: +21.04%
Pulse Biosciences
Apr 1, 2022
Maintains: Overweight
Price Target: $14 → $12
Current: $22.65
Upside: -47.02%
Anika Therapeutics
Mar 9, 2022
Downgrades: Equal-Weight
Price Target: n/a
Current: $15.81
Upside: -
Establishment Labs Holdings
Nov 10, 2021
Maintains: Overweight
Price Target: $88 → $90
Current: $65.47
Upside: +37.47%
STERIS
Nov 4, 2021
Maintains: Overweight
Price Target: $255 → $270
Current: $222.19
Upside: +21.52%
Glaukos
Nov 3, 2021
Upgrades: Overweight
Price Target: $60 → $68
Current: $122.07
Upside: -44.29%
Avanos Medical
Aug 4, 2021
Downgrades: Equal-Weight
Price Target: $60 → $45
Current: $24.62
Upside: +82.78%
Mar 23, 2020
Maintains: Overweight
Price Target: $425 → $275
Current: $135.07
Upside: +103.60%
Mar 23, 2020
Maintains: Overweight
Price Target: $56 → $37
Current: $26.68
Upside: +38.68%
Mar 23, 2020
Maintains: Overweight
Price Target: $75 → $60
Current: $61.41
Upside: -2.30%
Mar 23, 2020
Maintains: Overweight
Price Target: $48 → $35
Current: $59.95
Upside: -41.62%
Feb 22, 2018
Maintains: Equal-Weight
Price Target: $60 → $81
Current: $188.31
Upside: -56.99%